| Revision as of 12:02, 20 October 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,084 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').← Previous edit |
Latest revision as of 23:28, 20 January 2025 edit undoTsarivan613 (talk | contribs)Extended confirmed users5,021 editsm →History: Copy edit |
| (182 intermediate revisions by 85 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Anti-tuberculosis and anti-inflammatory drug}} |
|
{{Drugbox |
|
|
|
{{Use dmy dates|date=May 2024}} |
|
| verifiedrevid = 443350754 |
|
|
|
{{cs1 config |name-list-style=vanc |display-authors=6}} |
|
| IUPAC_name = 4-amino-2-hydroxy-benzoic acid |
|
|
|
{{Infobox drug |
|
|
| Watchedfields = changed |
|
|
| verifiedrevid = 477221040 |
|
| image = P-Aminosalicylic acid.svg |
|
| image = P-Aminosalicylic acid.svg |
|
|
| image_class = skin-invert-image |
|
| width = 180 |
|
|
|
| width = 200 |
|
| image2 = 4-Aminosalicylic acid 3d structure vander.png |
|
|
|
| alt = |
|
|
| image2 = 4-Aminosalicylic_acid_3d_structure.png |
|
|
| image_class2 = bg-transparent |
|
|
| width2 = 150 |
|
|
| alt2 = |
|
|
| caption = |
|
|
|
|
|
<!--Clinical data--> |
|
<!-- Clinical data --> |
|
| tradename = |
|
| pronounce = |
|
|
| tradename = Paser, Granupas, others |
|
| pregnancy_category = C |
|
|
|
| Drugs.com = {{drugs.com|monograph|aminosalicylic-acid}} |
|
| legal_UK = POM |
|
|
|
| MedlinePlus = |
|
| routes_of_administration = Oral |
|
|
|
| DailyMedID = Aminosalicylic acid |
|
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
|
| pregnancy_AU_comment = |
|
|
| pregnancy_category= |
|
|
| dependency_liability = |
|
|
| addiction_liability = |
|
|
| routes_of_administration = ] |
|
|
| class = |
|
|
| ATC_prefix = J04 |
|
|
| ATC_suffix = AA01 |
|
|
| ATC_supplemental = |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!-- Legal status --> |
|
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| bioavailability = |
|
|
|
| legal_AU_comment = |
|
|
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F--> |
|
|
| legal_BR_comment = |
|
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
|
| legal_CA_comment = |
|
|
| legal_DE = <!-- Anlage I, II, III or Unscheduled--> |
|
|
| legal_DE_comment = |
|
|
| legal_NZ = <!-- Class A, B, C --> |
|
|
| legal_NZ_comment = |
|
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> |
|
|
| legal_UK_comment = |
|
|
| legal_US = Rx-only |
|
|
| legal_US_comment = |
|
|
| legal_EU = Rx-only |
|
|
| legal_EU_comment = <ref name="Granupas EPAR" /> |
|
|
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> |
|
|
| legal_UN_comment = |
|
|
| legal_status = Rx-only |
|
|
|
|
|
<!-- Pharmacokinetic data --> |
|
|
| bioavailability = |
|
| protein_bound = 50–60% |
|
| protein_bound = 50–60% |
|
| metabolism = ] |
|
| metabolism = ] |
|
|
| metabolites = |
|
| elimination_half-life = |
|
|
|
| onset = |
|
| excretion = ] |
|
|
|
| elimination_half-life = |
|
|
| duration_of_action = |
|
|
| excretion = ] |
|
|
|
|
|
<!--Identifiers--> |
|
<!-- Identifiers --> |
|
| CASNo_Ref = {{cascite|correct|CAS}} |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 65-49-6 |
|
| CAS_number = 65-49-6 |
|
| CAS_supplemental = |
|
| CAS_supplemental = |
|
| ATC_prefix = J04 |
|
|
| ATC_suffix = AA01 |
|
|
| ATC_supplemental = |
|
|
| PubChem = 4649 |
|
| PubChem = 4649 |
|
|
| IUPHAR_ligand = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = DB00233 |
|
| DrugBank = DB00233 |
| Line 39: |
Line 81: |
|
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|
| ChEMBL = 1169 |
|
| ChEMBL = 1169 |
|
|
| NIAID_ChemDB = 020064 |
|
|
| PDB_ligand = BHA |
|
|
| synonyms = |
|
|
|
|
|
<!--Chemical data--> |
|
<!-- Chemical and physical data --> |
|
|
| IUPAC_name = 4-Amino-2-hydroxybenzoic acid |
|
| C=7 | H=7 | N=1 | O=3 |
|
|
|
| C=7 | H=7 | N=1 | O=3 |
|
| molecular_weight = 153.135 g/mol |
|
|
| smiles = O=C(O)c1ccc(cc1O)N |
|
| SMILES = OC(=O)c1ccc(N)cc1O |
|
| InChI = 1/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11) |
|
|
| InChIKey = WUBBRNOQWQTFEX-UHFFFAOYAO |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11) |
|
| StdInChI = 1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11) |
|
|
| StdInChI_comment = |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey = WUBBRNOQWQTFEX-UHFFFAOYSA-N |
|
| StdInChIKey = WUBBRNOQWQTFEX-UHFFFAOYSA-N |
|
|
| density = |
|
|
| density_notes = |
|
| melting_point = 150.5 |
|
| melting_point = 150.5 |
|
|
| melting_high = |
|
|
| melting_notes = |
|
|
| boiling_point = |
|
|
| boiling_notes = |
|
|
| solubility = |
|
|
| sol_units = |
|
|
| specific_rotation = |
|
}} |
|
}} |
|
|
|
|
|
|
<!-- Definition and medical uses --> |
|
'''4-aminosalicylic acid''', commonly known as PAS, is an ] used to treat ]. This ] has been use since the 1940s for the treatment of ]s (IBDs), where it has shown greater potency in ulcerative colitis and ]. It is thought to act via ] (nuclear factor-kappa B) inhibition and free radical scavenging. 5-Aminosalicylic acid, sold under the name ], is a closely related compound that also has medical uses. |
|
|
|
'''4-Aminosalicylic acid''', also known as '''''para''-aminosalicylic acid''' ('''PAS''') and sold under the brand name '''Paser''' among others, is an ] primarily used to treat ].<ref name=WHO2008>{{cite book | title = WHO Model Formulary 2008 | year = 2009 | isbn = 9789241547659 | vauthors = ((World Health Organization)) | veditors = Stuart MC, Kouimtzi M, Hill SR | hdl = 10665/44053 | author-link = World Health Organization | publisher = World Health Organization | hdl-access=free |page=140}}</ref> Specifically it is used to treat active ] together with other ].<ref name=AHFS2016/> It has also been used as a second line agent to ] in people with ] such as ] and ].<ref name=AHFS2016/> It is typically taken by mouth.<ref name=AHFS2016/> |
|
|
|
|
|
<!-- Side effects and mechanism --> |
|
|
Common side effects include nausea, abdominal pain, and diarrhea.<ref name=AHFS2016/> Other side effects may include ] and ].<ref name=AHFS2016/> It is not recommended in people with ].<ref name=AHFS2016/> While there does not appear to be harm with use during ] it has not been well studied in this population.<ref name=AHFS2016/> 4-Aminosalicylic acid is believed to work by blocking the ability of bacteria to make ].<ref name=AHFS2016>{{cite web|title=Aminosalicylic Acid|url=https://www.drugs.com/monograph/aminosalicylic-acid.html|publisher=The American Society of Health-System Pharmacists|access-date=8 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161220231049/https://www.drugs.com/monograph/aminosalicylic-acid.html|archive-date=20 December 2016}}</ref> |
|
|
|
|
|
<!-- History and culture --> |
|
|
4-Aminosalicylic acid was first made in 1902, and came into medical use in 1943.<ref name=Lancet2015>{{cite journal | vauthors = Donald PR, Diacon AH | title = Para-aminosalicylic acid: the return of an old friend | journal = The Lancet. Infectious Diseases | volume = 15 | issue = 9 | pages = 1091–1099 | date = September 2015 | pmid = 26277036 | doi = 10.1016/s1473-3099(15)00263-7 }}</ref> It is on the ].<ref name="WHO23rd">{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref> |
|
|
|
|
|
==Medical uses== |
|
==Medical uses== |
|
|
The main use for 4-aminosalicylic acid is for the treatment of tuberculosis infections.<ref name="Granupas EPAR">{{cite web | title=Granupas (previously Para-aminosalicylic acid Lucane) | website=] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/granupas-previously-para-aminosalicylic-acid-lucane | access-date=3 April 2020 | archive-date=15 August 2020 | archive-url=https://web.archive.org/web/20200815111328/https://www.ema.europa.eu/en/medicines/human/EPAR/granupas-previously-para-aminosalicylic-acid-lucane | url-status=live }}</ref><ref name="Paser FDA label">{{cite web | title=Paser- aminosalicylic acid granule, delayed release | website=DailyMed | date=1 May 2010 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6 | access-date=3 April 2020 | archive-date=3 August 2020 | archive-url=https://web.archive.org/web/20200803175339/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6 | url-status=live }}</ref> |
|
Aminosalicylic acid was introduced to clinical use in 1948. It was the second antibiotic found to be effective in the treatment of tuberculosis, after ]. PAS formed part of the standard ] prior to the introduction of ] and ].<ref>{{cite journal|author=Mitchison DA|title=Role of individual drugs in the chemotherapy of tuberculosis Role of individual drugs in the chemotherapy of tuberculosis|journal=Int J Tuberc Lung Dis|volume=4|issue=9|pages=796–806|pmid=10985648|year=2000}}</ref> |
|
|
|
|
|
|
Its potency is less than that of the current five first-line drugs (], ], ], ], and ]) for treating tuberculosis, but it is still useful in the treatment of ]. PAS is always used in combination with other anti-TB drugs. |
|
In the United States, 4-aminosalicylic acid is indicated for the treatment of tuberculosis in combination with other active agents.<ref name="Paser FDA label" /> |
|
|
|
|
|
|
In the European Union, it is used in combination with other medicines to treat adults and children from 28 days of age who have multi-drug resistant tuberculosis when combinations without this medicine cannot be used, either because the disease is resistant to them or because of their side effects.<ref name="Granupas EPAR" /> |
|
The dose when treating tuberculosis is 150 mg/kg/day divided into two to four daily doses; the usual adult dose is therefore approximately 2 to 4 grams four times a day. It is sold in the US as "Paser", which comes in the form of 4 g packets of delayed-release granules. The drug should be taken with acid food or drink (orange, apple or tomato juice).<ref>{{cite web|title=Paser|publisher=RxList|url=http://www.rxlist.com/cgi/generic/paser.htm|accessdate=2008-10-10}}</ref> PAS was once available in a combination formula with isoniazid called Pasinah<ref>{{cite journal|title=Lichen scrofulosorum: A report of four cases|author=Smith NP, Ryan TJ, Sanderson KV, Sarkany I|journal=Br J Dermatol|volume=94|issue=3|pages=319–325|doi=10.1111/j.1365-2133.1976.tb04391.x|pmid=1252363|year=1976}}</ref> or Pycamisan 33<ref>{{cite journal|title=Two incidents of tuberculous infection by milk from attested herds|author=Black JM|journal=Br Med J|pages=1732-1735|year=1961}}</ref> |
|
|
|
|
|
|
|
===Tuberculosis=== |
|
PAS has also been used in the treatment of ],<ref>{{cite journal|author=Daniel F, Seksik P, Cacheux W, Jian R, Marteau P|title=Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis|journal=Inflamm Bowel Dis|volume=10|issue=3|pages=258–260|pmid=15290921|doi=10.1097/00054725-200405000-00013|year=2004}}</ref> but has been superseded by other drugs such as ] and ]. |
|
|
|
Aminosalicylic acid was introduced to clinical use in 1944. It was the second antibiotic found to be effective in the treatment of tuberculosis, after ]. PAS formed part of the standard ] prior to the introduction of ] and ].<ref>{{cite journal | vauthors = Mitchison DA | title = Role of individual drugs in the chemotherapy of tuberculosis | journal = The International Journal of Tuberculosis and Lung Disease | volume = 4 | issue = 9 | pages = 796–806 | date = September 2000 | pmid = 10985648 }}</ref> |
|
|
|
|
|
|
Its potency is less than that of the current five first-line drugs (], rifampicin, ], ], and streptomycin) for treating tuberculosis and its cost is higher, but it is still useful in the treatment of ].<ref name="long" /> PAS is always used in combination with other anti-TB drugs.{{citation needed|date=August 2022}} |
|
PAS has also been used for manganese chelation therapy, and seems to be superior to other chelation protocols (ex.: EDTA) in this regard (http://www.ncbi.nlm.nih.gov/pubmed/16766929 -> Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study). |
|
|
|
|
|
|
|
The dose when treating tuberculosis is 150 mg/kg/day divided into two to four daily doses; the usual adult dose is therefore approximately 2 to 4 grams four times a day. It is sold in the US as "Paser" by Jacobus Pharmaceutical, which comes in the form of 4 g packets of delayed-release granules. The drug should be taken with acid food or drink (], ] or ]).<ref>{{cite web|title=Paser |publisher=RxList |url=http://www.rxlist.com/cgi/generic/paser.htm |access-date=10 October 2008 |archive-url=https://web.archive.org/web/20080913183444/http://www.rxlist.com/cgi/generic/paser.htm |archive-date=13 September 2008 |url-status=dead }}</ref> PAS was once available in a combination formula with isoniazid called Pasinah<ref>{{cite journal | vauthors = Smith NP, Ryan TJ, Sanderson KV, Sarkany I | title = Lichen scrofulosorum. A report of four cases | journal = The British Journal of Dermatology | volume = 94 | issue = 3 | pages = 319–325 | date = March 1976 | pmid = 1252363 | doi = 10.1111/j.1365-2133.1976.tb04391.x | s2cid = 26281951 }}</ref> or Pycamisan 33.<ref>{{cite journal | vauthors = Black JM, Sutherland IB | title = Two Incidents of Tuberculous Infection by Milk from Attested Herds | journal = British Medical Journal | volume = 1 | issue = 5241 | pages = 1732–1735 | date = June 1961 | pmid = 20789163 | pmc = 1954350 | doi = 10.1136/bmj.1.5241.1732 }}</ref> |
|
==Pharmacology== |
|
|
With ], aminosalicylic acid is ] to produce ] and ]. |
|
|
|
|
|
|
|
4-Aminosalicylic acid was approved for medical use in the United States in June 1994, and for medical use in the European Union in April 2014.<ref>{{cite web | title=Paser: FDA-Approved Drugs | website=U.S. ] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=074346 | access-date=3 April 2020 | archive-date=15 September 2020 | archive-url=https://web.archive.org/web/20200915060651/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=074346 | url-status=live }}</ref><ref name="Granupas EPAR" /> |
|
The U.S. ] assigned PAS to ] C, indicating that it is not known whether it will harm an ]. |
|
|
|
|
|
|
===Inflammatory bowel disease=== |
|
|
4-Aminosalicylic acid has also been used in the treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease),<ref name="xl">{{cite journal | vauthors = Daniel F, Seksik P, Cacheux W, Jian R, Marteau P | title = Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis | journal = Inflammatory Bowel Diseases | volume = 10 | issue = 3 | pages = 258–260 | date = May 2004 | pmid = 15290921 | doi = 10.1097/00054725-200405000-00013 }}</ref> but has been superseded by other drugs such as ] and ]. |
|
|
|
|
|
===Others=== |
|
|
4-Aminosalicylic acid has been investigated for the use in ] ], and a 17-year follow-up study shows that it might be superior to other chelation protocols such as ].<ref>{{cite journal | vauthors = Jiang YM, Mo XA, Du FQ, Fu X, Zhu XY, Gao HY, Xie JL, Liao FL, Pira E, Zheng W | title = Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study | journal = Journal of Occupational and Environmental Medicine | volume = 48 | issue = 6 | pages = 644–649 | date = June 2006 | pmid = 16766929 | pmc = 4180660 | doi = 10.1097/01.jom.0000204114.01893.3e }}</ref> |
|
|
|
|
|
==Side effects== |
|
==Side effects== |
|
Gastrointestinal ] (nausea, vomiting, diarrhoea) are common; the delayed-release formulation is meant to help overcome this problem. It is also a cause of drug-induced ]. Patients with ] should avoid taking aminosalicylic acid as it causes ]. Thyroid ] is also a side-effect because aminosalicylic acid inhibits the synthesis of ]s. Drug interactions include elevated ] levels. When taken with ], the levels of ] in the blood fall by about half.<ref>{{cite journal|author=Boman G|title=Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid|year=1974|volume=7|issue=3|pages=217–25|doi=10.1007/BF00560384|pmid=4854257|journal=European journal of clinical pharmacology}}</ref> |
|
Gastrointestinal ] (nausea, vomiting, diarrhoea) are common; the delayed-release formulation is meant to help overcome this problem.<ref>{{cite journal | vauthors = Das KM, Eastwood MA, McManus JP, Sircus W | title = Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype | journal = The New England Journal of Medicine | volume = 289 | issue = 10 | pages = 491–495 | date = September 1973 | pmid = 4146729 | doi = 10.1056/NEJM197309062891001 }}</ref> It is also a cause of drug-induced ]. Patients with ] should avoid taking aminosalicylic acid as it causes ].<ref>{{cite journal | vauthors = Szeinberg A, Sheba C, Hirshorn N, Bodonyi E | title = Studies on erthrocytes in cases with past history of favism and drug-induced acute hemolytic anemia | journal = Blood | volume = 12 | issue = 7 | pages = 603–613 | date = July 1957 | pmid = 13436516 | doi = 10.1182/blood.V12.7.603.603 | doi-access = free }}</ref> Thyroid ] is also a side-effect because aminosalicylic acid inhibits the synthesis of ]s.<ref>{{cite journal | vauthors = Macgregor AG, Somner AR | title = The anti-thyroid action of para-aminosalicylic acid | journal = Lancet | volume = 267 | issue = 6845 | pages = 931–936 | date = November 1954 | pmid = 13213079 | doi = 10.1016/S0140-6736(54)92552-0 }}</ref> |
|
|
|
|
|
|
Drug interactions include elevated ] levels. When taken with rifampicin, the levels of rifampicin in the blood fall by about half.<ref>{{cite journal | vauthors = Boman G | title = Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid | journal = European Journal of Clinical Pharmacology | volume = 7 | issue = 3 | pages = 217–225 | year = 1974 | pmid = 4854257 | doi = 10.1007/BF00560384 | s2cid = 24202603 }}</ref> |
|
== History == |
|
|
PAS was discovered by the Swedish chemist ] upon the report that the tuberculosis bacterium avidly metabolized ]. Lehmann first tried PAS as an oral TB therapy late in 1944. The first patient made a dramatic recovery. The drug proved better than ], which had nerve toxicity and to which TB could easily develop resistance. Late in the 1940s, researchers at Britain's ] demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone. Aminosalicylic acid is sold in the U.S. by Jacobus Pharmaceutical as Paser. |
|
|
|
|
|
|
|
It is not known whether it will harm an ].<ref name="Drugs.com pregnancy">{{cite web | title=Aminosalicylic acid (Paser) Use During Pregnancy | website=Drugs.com | date=28 February 2020 | url=https://www.drugs.com/pregnancy/aminosalicylic-acid.html | access-date=3 April 2020 | archive-date=15 September 2020 | archive-url=https://web.archive.org/web/20200915062959/https://www.drugs.com/pregnancy/aminosalicylic-acid.html | url-status=live }}</ref> |
|
==Synthesis== |
|
|
PAS is manufactured by the carboxylation of ].<ref name=Mitchell_Waring>Mitchell, S.C. & Waring, R.H. “Aminophenols.” In Ullmann’s Encyclopedia of Industrial Chemistry; 2002 Wiley-VCH, {{DOI|10.1002/14356007.a02_099}}</ref> |
|
|
|
|
|
|
==Other names== |
|
==Pharmacology== |
|
|
With ], 4-aminosalicylic acid is ] to produce ] and ].<ref>{{cite journal | vauthors = Vetuschi C, Ragno G, Mazzeo P | title = Determination of p-aminosalicylic acid and m-aminophenol by derivative UV-spectrophotometry | journal = Journal of Pharmaceutical and Biomedical Analysis | volume = 6 | issue = 4 | pages = 383–391 | year = 1988 | pmid = 16867404 | doi = 10.1016/0731-7085(88)80003-7 }}</ref> |
|
Like many commercially significant compounds, PAS has many names including ''para''-aminosalicylic acid, ''p''-aminosalicylic acid, 4-ASA, and simply P. |
|
|
|
|
|
|
|
===Mode of action=== |
|
<gallery> |
|
|
|
4-Aminosalicylic acid has been shown to be a pro-drug and it is incorporated into the ] pathway by dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate a hydroxyl dihydrofolate (Hydroxy-H<sub>2</sub>Pte and Hydroxy-H<sub>2</sub>PteGlu) ], which competes with dihydrofolate at the binding site of dihydrofolate reductase (]). The binding of Hydroxy-H<sub>2</sub>PteGlu to dihydrofolate reductase will block the enzymatic activity.<ref>{{cite journal | vauthors = Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR | title = para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis | journal = The Journal of Biological Chemistry | volume = 288 | issue = 32 | pages = 23447–23456 | date = August 2013 | pmid = 23779105 | pmc = 3789992 | doi = 10.1074/jbc.m113.475798 | doi-access = free }}</ref> |
|
File:4-Aminosalicylic_acid_3d_structure.png |
|
|
|
|
|
</gallery> |
|
|
|
=== Mechanism of action === |
|
|
Some studies have shown that principal antitubercular action of PAS occurs via poisoning of folate metabolism.<ref>{{cite journal | vauthors = Minato Y, Thiede JM, Kordus SL, McKlveen EJ, Turman BJ, Baughn AD | title = Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance | journal = Antimicrobial Agents and Chemotherapy | volume = 59 | issue = 9 | pages = 5097–5106 | date = September 2015 | pmid = 26033719 | pmc = 4538520 | doi = 10.1128/AAC.00647-15 }}</ref> |
|
|
|
|
|
=== Resistance === |
|
|
It was initially thought that resistance of 4-aminosalicylic acid came from a mutation affecting dihydrofolate reductase (DHFR). However, it was discovered that it was caused by a mutation affecting the dihydrofolate synthesis (DHFS) enzyme activity. The mutations of isoleucine 43, arginine 49, serine 150, phenylalanine 152, glutamate 153, and alanine 183 were found to affect the binding pocket of the dihydrofolate synthase enzyme. This will reduce the ability for hydroxy-H<sub>2</sub>Pte to bind to dihydrofolate synthase and preventing 4-aminosalicylic acid from poisoning the folate metabolism.<ref>{{cite journal | vauthors = Zhao F, Wang XD, Erber LN, Luo M, Guo AZ, Yang SS, Gu J, Turman BJ, Gao YR, Li DF, Cui ZQ, Zhang ZP, Bi LJ, Baughn AD, Zhang XE, Deng JY | title = Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis | journal = Antimicrobial Agents and Chemotherapy | volume = 58 | issue = 3 | pages = 1479–1487 | date = 1 January 2014 | pmid = 24366731 | pmc = 3957869 | doi = 10.1128/aac.01775-13 }}</ref> |
|
|
|
|
|
== History == |
|
|
4-Aminosalicylic acid was first synthesized by Seidel and Bittner in 1902.<ref name=Lancet2015/> It was rediscovered by the Swedish chemist ] upon the report that the tuberculosis bacterium avidly metabolized ].<ref>{{cite journal | vauthors = Lehmann J | title = The treatment of tuberculosis in Sweden with para-aminosalicylic acid; a review | journal = Diseases of the Chest | volume = 16 | issue = 6 | pages = 684–703, illust | date = December 1949 | pmid = 15396516 | doi = 10.1378/chest.16.6.684 }}</ref> Lehmann first tried PAS as an oral TB therapy late in 1944. The first patient made a dramatic recovery.<ref>{{cite journal | vauthors = Lehmann J | title = Para-aminosalicylic acid in the treatment of tuberculosis | journal = Lancet | volume = 1 | issue = 6384 | pages = 15–16 | date = January 1946 | pmid = 21008766 | doi = 10.1016/s0140-6736(46)91185-3 }}</ref> The drug proved better than streptomycin, which had ] and to which TB could easily develop resistance. In 1948, researchers at Britain's ] demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone, and established the principle of combination therapy for tuberculosis.<ref name="long">{{cite journal | vauthors = Fox W, Ellard GA, Mitchison DA | title = Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications | journal = The International Journal of Tuberculosis and Lung Disease | volume = 3 | issue = 10 Suppl 2 | pages = S231–S279 | date = October 1999 | pmid = 10529902 }}</ref><ref name=Lancet2015 /> |
|
|
|
|
|
==Other names== |
|
|
4-Aminosalicylic acid has many names including ''para''-aminosalicylic acid, ''p''-aminosalicylic acid, 4-ASA, and simply P.{{medcn|date=April 2020}} |
|
|
|
|
|
==External links== |
|
== References == |
|
|
{{Reflist}} |
|
* |
|
|
* |
|
|
|
|
|
|
|
== Further reading == |
|
==References== |
|
|
|
* {{cite journal | vauthors = | title = Para-aminosalicylic acid | journal = Tuberculosis | volume = 88 | issue = 2 | pages = 137–138 | date = March 2008 | pmid = 18486053 | pmc = 1822430 | doi = 10.1016/S1472-9792(08)70019-2 | doi-access = free }} |
|
{{reflist}} |
|
|
|
|
|
|
{{Antimycobacterials}} |
|
{{Antimycobacterials}} |
|
|
{{Portal bar | Medicine}} |
|
|
{{Authority control}} |
|
|
|
|
|
{{DEFAULTSORT:Aminosalicylic acid, 4-}} |
|
{{DEFAULTSORT:Aminosalicylic Acid, 4-}} |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|